Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized placebo-controlled dose-ranging study of inhaled ALX-0171 in hospitalized infants and young children with RSV lower respiratory tract infection
MOH_2017-02-28_000132Phase 2Not yet recruiting
- Sponsor
- Ablynx
- Start
- Sep 2016
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of gontivimab in respiratory syncytial virus disease (RSV) (4 arms), sponsored by Ablynx. Planned start Sep 2016; status: not yet recruiting.
02
Drugs
gontivimab
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on MOH_2017-02-28_000132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-02-28_000132.